Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of β-hemoglobinopathies

• Príomhchruthaitheoirí: Vigneshwaran Venkatesan (Údar), Abisha Crystal Christopher (Údar), Manuel Rhiel (Údar), Manoj Kumar K. Azhagiri (Údar), Prathibha Babu (Údar), Kaivalya Walavalkar (Údar), Bharath Saravanan (Údar), Geoffroy Andrieux (Údar), Sumathi Rangaraj (Údar), Saranya Srinivasan (Údar), Karthik V. Karuppusamy (Údar), Annlin Jacob (Údar), Abhirup Bagchi (Údar), Aswin Anand Pai (Údar), Yukio Nakamura (Údar), Ryo Kurita (Údar), Poonkuzhali Balasubramanian (Údar), Rekha Pai (Údar), Srujan Kumar Marepally (Údar), Kumarasamypet Murugesan Mohankumar (Údar), Shaji R. Velayudhan (Údar), Melanie Boerries (Údar), Dimple Notani (Údar), Toni Cathomen (Údar), Alok Srivastava (Údar), Saravanabhavan Thangavel (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Elsevier, 2023-06-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Reactivation of fetal hemoglobin (HbF) is a commonly adapted strategy to ameliorate β-hemoglobinopathies. However, the continued production of defective adult hemoglobin (HbA) limits HbF tetramer production affecting the therapeutic benefits. Here, we evaluated deletional hereditary persistence of f...